SCHEMBL14699642

SCHEMBL14699642

[N-]=[N+]=NCc1ccccc1C(=O)Cl

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KAT2B Q92831 2/20 0.40
ALDH1A1 P00352 2/20 0.40
ALOX15 P16050 2/20 0.40
MCL1 Q07820 1/20 0.34
MYC P01106 1/20 0.33
FOLH1 Q04609 1/20 0.33
HDAC3 O15379 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
CTSD P07339 1/20 0.31
CES2 O00748 1/20 0.31
CES1 P23141 1/20 0.31
HPGD P15428 1/20 0.30
TP53 P04637 1/20 0.30
HTT P42858 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27814810 0.85 KAT2B (0.38) KAT2BALDH1A1ALOX15MCL1TSHR
SCHEMBL14699641 0.84 FOLH1 (0.49) KAT2BALDH1A1ALOX15FOLH1HDAC8
SCHEMBL16588078 0.83 CTSD (0.46) KAT2BALDH1A1MYCHDAC3HDAC1
SCHEMBL15763694 0.83 KAT2B (0.40) KAT2BALDH1A1MCL1MYCHDAC3
Hydrochloric Acid SCHEMBL29790654 0.81 KDM4E (0.40) KAT2BALDH1A1MCL1HPGDTSHR
SCHEMBL15353860 0.79 ALDH1A1 (0.53) ALDH1A1ALOX15MYCHPGDHTT
SCHEMBL28312340 0.77 KAT2B (0.47) KAT2BALDH1A1MCL1MYC
SCHEMBL14009414 0.76 L3MBTL1 (0.49) ALDH1A1HDAC3HDAC1HDAC2HDAC8
SCHEMBL26110049 0.76 FOLH1 (0.47) KAT2BALDH1A1ALOX15MYCFOLH1
SCHEMBL16208886 0.75 KAT2B (0.39) KAT2BALOX15MCL1MYCCES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114199974-A Screening method of specific binding target protein based on isomer 南开大学 2022-03-18 CN claimed
US-11180523-B2 Design, synthesis and use of synthetic nucleotides comprising charge mass tags QUANTUMDX GROUP LIMITED (GB) 2021-11-23 US disclosed
US-11180523-B2 Design, synthesis and use of synthetic nucleotides comprising charge mass tags QUANTUMDX GROUP LIMITED (GB) 2021-11-23 US disclosed
US-10759824-B2 Design, synthesis and use of synthetic nucleotides comprising charge mass tags QUANTUMDX GROUP LIMITED (GB) 2020-09-01 US disclosed
US-10759824-B2 Design, synthesis and use of synthetic nucleotides comprising charge mass tags QUANTUMDX GROUP LIMITED (GB) 2020-09-01 US disclosed
US-20190248827-A1 DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS QUANTUMDX GROUP LIMITED (GB) 2019-08-15 US disclosed
US-20190248827-A1 DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS QUANTUMDX GROUP LIMITED (GB) 2019-08-15 US disclosed
US-10273261-B2 Design, synthesis and use of synthetic nucleotides comprising charge mass tags QUANTUMDX GROUP LIMITED (GB) 2019-04-30 US disclosed
US-10273261-B2 Design, synthesis and use of synthetic nucleotides comprising charge mass tags QUANTUMDX GROUP LIMITED (GB) 2019-04-30 US disclosed
US-20190004055-A1 DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS QUANTUMDX GROUP LIMITED (GB) 2019-01-03 US disclosed
US-8569476-B2 Method for preparing oligonucleotide Suzhou Ribo Life Science Co., Ltd. (CN) 2013-10-29 US disclosed
EP-2380896-B1 A METHOD FOR PREPARING OLIGONUCLEOTIDE SUZHOU RIBO LIFE SCIENCE CO LTD (CN) 2013-02-13 EP disclosed
EP-2386563-A1 Novel O-acetylated decasaccharides Institut Pasteur (FR) 2011-11-16 EP disclosed
EP-2386563-A1 Novel O-acetylated decasaccharides Institut Pasteur (FR) 2011-11-16 EP disclosed
EP-2380896-A1 A METHOD FOR PREPARING OLIGONUCLEOTIDE Suzhou Ribo Life Science Co., Ltd (CN) 2011-10-26 EP disclosed
US-20110237786-A1 METHOD FOR PREPARING OLIGONUCLEOTIDE SUZHOU RIBO LIFE SCIENCE CO., LTD (CN) 2011-09-29 US disclosed
US-20110237786-A1 METHOD FOR PREPARING OLIGONUCLEOTIDE SUZHOU RIBO LIFE SCIENCE CO., LTD (CN) 2011-09-29 US disclosed
CN-101684136-A Method for preparing oligonucleotides SHENZHEN RIBO BIOTECHNOLOGY CO 2010-03-31 CN disclosed
US-20090233280-A1 METHOD OF ACQUIRING INFORMATION REGARDING BASE SEQUENCE AND INFORMATION READING DEVICE FOR THE SAME CANON KABUSHIKI KAISHA (JP) 2009-09-17 US disclosed
WO-2007077952-A1 METHOD AND DEVICE FOR DETERMINING A NUCLEIC ACID ALLELE OR BASE SEQUENCE CANON KABUSHIKI KAISHA (JP) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11180523-B2 Design, synthesis and use of synthetic nucleotides comprising charge mass tags POLM, RNGTT, TYMP KAT2B 1816/4885ALDH1A1 3873/4885ALOX15 4140/4885
US-20190004055-A1 DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS POLM, RNGTT, TYMP KAT2B 1816/4885ALDH1A1 3873/4885ALOX15 4140/4885
US-10759824-B2 Design, synthesis and use of synthetic nucleotides comprising charge mass tags POLM, RNGTT, TYMP KAT2B 1816/4885ALDH1A1 3873/4885ALOX15 4140/4885
US-20190248827-A1 DESIGN, SYNTHESIS AND USE OF SYNTHETIC NUCLEOTIDES COMPRISING CHARGE MASS TAGS POLM, RNGTT, TYMP KAT2B 1816/4885ALDH1A1 3873/4885ALOX15 4140/4885
US-10273261-B2 Design, synthesis and use of synthetic nucleotides comprising charge mass tags POLM, RNGTT, TYMP KAT2B 1816/4885ALDH1A1 3873/4885ALOX15 4140/4885
US-20110237786-A1 METHOD FOR PREPARING OLIGONUCLEOTIDE POLRMT, POLR2H, RNGTT KAT2B 2230/4885ALDH1A1 3247/4885ALOX15 1143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.